Enhanced accumulation of ribavirin and its metabolites in liver versus erythrocytes in mice administered with the liver targeted drug.
Ribavirin increases the efficacy of alpha-interferon in chronic hepatitis C, but accumulates in erythrocytes causing haemolysis. To reduce this side effect we conjugated ribavirin with lactosaminated poly-L-lysine. In mice administered with the same dose of free or conjugated [3H]ribavirin we determined the levels of radioactivity in liver and erythrocytes and measured the hepatic concentrations of ribavirin triphosphate. Moreover, we determined the doses of free and conjugated ribavirin producing a 50% reduction in the virus titre (ED50) in liver of mice infected with murine hepatitis virus. In mice treated with the conjugate, the ratio dpm in liver/dpm in erythrocytes was 2.2- or 4.7-fold higher than in animals administered with the free drug given intramuscularly or orally, respectively. The concentration of [3H]ribavirin triphosphate was found to be 2-fold higher in mice injected with the conjugated drug than in animals orally treated with free ribavirin. In murine hepatitis virus infected mice, the ED50 was 27.4 micrograms/g for conjugated ribavirin and 47.2 micrograms/g for the free drug. These results support the possibility that conjugated ribavirin may produce the same pharmacological activity in liver as the free drug but with a reduced haemolysis.